Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

Cancer Biology and Therapy

Volumn 10, Issue 9, 2010, Pages 903-917

  Mitchell, Clint ^a   Yacoub, Adly ^a   Hamed, Hossein ^a   Martin, Aditi Pandya ^a   Bareford, M Danielle ^a   Eulitt, Patrick ^a   Yang, Chen ^a   Nephew, Kenneth P ^b   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BAK; BCL 2 inhibitor; CDK inhibitor; Flavopiridol; Lapatinib; MCL 1; Obatoclax; Roscovitine; RTK inhibitor

Indexed keywords

FLAVOPIRIDOL; LAPATINIB; OBATOCLAX; PROTEIN MCL 1; ROSCOVITINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RADIOSENSITIZATION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DRUG SYNERGISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FLAVONOIDS; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKOUT TECHNIQUES; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR TARGETED THERAPY; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PURINES; PYRROLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78549257149     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.9.13273     Document Type: Article

References (44)

1. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000; 275:28345-8.
2. De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 1996; 93:2735-40.
3. Wesierska-Gadek J, Krystof V. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia? Ann N Y Acad Sci 2009; 1171:228-41.
4. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001; 276:31793-9.
5. Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investig New Drugs 1999; 17:313-20.
6. 1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56:2973-8.
7. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998; 91:458-65.
8. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and downregulation of Mcl-1. Clin Cancer Res 2002; 11:3527-38.
9. WAF1/CIP1 downregulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004; 65:571-81.
10. Takada Y, Aggarwal BB. Flavopiridol inhibits NFκB activation induced by various carcinogens and inflammatory agents through inhibition of IκBα kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2 and matrix metalloprotease-9. J Biol Chem 2004; 279:4750-9. (Pubitemid 38199070)
11. Almenara J, Rosato RR, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (Vorinostat). Leukemia 2002; 16:1331-43.
12. Gao N, Dai Y, Rahmani M, Dent P, Grant S. Contribution of disruption of the nuclear factorkappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol 2004; 66:956-63.
13. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009; 9:66-76.
14. Carter CA, Kelly RJ, Giaccone G. Small-molecule inhibitors of the human epidermal receptor family. Expert Opin Investig Drugs 2009; 18:1829-42.
15. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, et al. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 2008; 9:614-30.
16. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM. Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells. Clin Cancer Res 2009; 15:1585-92.
17. Hida T, Ogawa S, Park JC, Park JY, Shimizu J, Horio Y, Yoshida K. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther 2009; 9:17-35.
18. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-11. (Pubitemid 39209661)
19. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-7.
20. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104:20932-7.
21. Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13:485-98.
22. Mueller KL, Hunter LA, Ethier SP, Boerner JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008; 68:3314-22.
23. Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, et al. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Mol Pharmacol 2008; 74:807-22.
24. Grant S, Dent P. Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias. Curr Drug Targets 2007; 8:751-9.
25. Grant S. Is the focus moving toward a combination of targeted drugs? Best Pract Res Clin Haematol 2008; 21:629-37.
26. Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 2009; 218:13-21.
27. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15:1126-32.
28. Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009; 9:321-6.
29. Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 Synergizes with Chemotherapy to Kill Head and Neck Squamous Cell Carcinoma Cells Via a NOXA-Mediated Mol Pharmacol 2009; 75:1231-9.
30. Park MA, Zhang G, Mitchell C, Rahmani M, Hamed H, Hagan MP, et al. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17- demethoxy-geldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther 2008; 7:2633-48.
31. Park MA, Yacoub A, Sarkar D, Emdad L, Rahmani M, Spiegel S, et al. PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy 2008; 4:513-5.
32. Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, et al. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70 kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol 2008; 73:1168-84. (Pubitemid 351439199)
33. Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008; 7:1648-62.
34. Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, et al. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. J Biol Chem 2008; 283:24343-58.
35. Mitchell C, Park MA, Zhang G, Yacoub A, Curiel DT, Fisher PB, et al. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol Cancer Ther 2007; 6:3101-12.
36. Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther 2009; 8:2084-96.
37. Yip AY, Tse LA, Ong EY, Chow LW. Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review. Anticancer Drugs 2010; [Epub ahead of print].
38. Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009; 31:2332-48.
39. Henson ES, Johnston JB, Los M, Gibson SB. Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. Biologics 2007; 1:229-39.
40. Zoppoli G, Moran E, Soncini D, Cea M, Garuti A, Rocco I, et al. Ras-induced resistance to lapatinib is overcome by MEK inhibition. Curr Cancer Drug Targets 2010; 10:168-75.
41. Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, et al. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res 2010; 16:912-23.
42. Newcomb EW, Lymberis SC, Lukyanov Y, Shao Y, Schnee T, Devitt M, et al. Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol. Cell Cycle 2006; 5:93-9.
43. Pan J, Cheng C, Verstovsek S, Chen Q, Jin Y, Cao Q. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett 2010; [Epub ahead of print].
44. Yang G, Wu L, Chen S, Zhu L, Huang P, Tong L, et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs radiation-induced bystander effect. Br J Cancer 2009; 100:1912-6.